Horizon Therapeutics (HZNP) Tops Q3 EPS by 19c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance; Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectatio
November 2, 2022 7:00 AM EDT
Third-Quarter 2022 Results:
-- Net Sales of $925.4 Million --
-- GAAP Net Income of $135.8 Million; Adjusted EBITDA of $335.3 Million, Which Includes $19.0 Million of Acquired IPR&D and Milestones Expenses --
-- TEPEZZA® (teprotumumab-trbw) Net Sales of $490.9 Million --
-- KRYSTEXXA® (pegloticase injection) Net Sales of $191.6 Million --
-- Cash Position of $2.13 Billion as of Sept. 30, 2022 --
Full-Year 2022 Guidance and Peak Annual Net Sales Expectations:
-- Increasing Full-Year 2022 Net Sales Guidance to $3.59 Billion to $3.61 Billion --
--... More
